1. Industry corner: perspectives and controversies
- Author
-
John Zalcberg, Ian Kerridge, Narcyz Ghinea, and Wendy Lipworth
- Subjects
0301 basic medicine ,Drug Costs ,Health Services Accessibility ,03 medical and health sciences ,0302 clinical medicine ,Order (exchange) ,Neoplasms ,Clearing ,Humans ,Medicine ,Health technology assessment ,Resource allocation ,Access to medicines ,Health Services Needs and Demand ,Health Equity ,business.industry ,Therapies, Investigational ,Subsidy ,Hematology ,Public relations ,2201 Applied ethics ,Health equity ,1117 Public Health and Health Sciences ,030104 developmental biology ,Oncology ,Conceptual framework ,030220 oncology & carcinogenesis ,business - Abstract
Oncologists have an important role to play in debates about access to high cost cancer medicines. But in order for oncologists to be able to fulfil this role they need to have a solid understanding of the contexts of debates about access to high cost medicines, of the parameters that everyone can agree upon, and of the points of disagreement that need to be resolved. In this article, we offer a conceptual framework that oncologists (and other stakeholders) could use to guide more focused, systematic and ultimately mutually beneficial discussions about the subsidization of high cost cancer medicines.
- Published
- 2019
- Full Text
- View/download PDF